TAMPA, Fla., May 28, 2026 — Psilera Inc. (“Psilera”), a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, today announced the successful closing of an oversubscribed $8.8 million Series Seed extension funding round led by a syndicate of institutional and strategic investors.
The company intends to use the funds to advance its lead clinical asset, PSIL-006, towards first-in-human trials in 2027. PSIL-006 is a first-in-class neuroplastogen designed to harness the therapeutic benefits of traditional psychedelic compounds while minimizing hallucinogenic effects and cardiovascular risks.
“This funding marks a pivotal inflection point for Psilera,” said Dr. Chris Witowski, Co-Founder and CEO of Psilera. “With the continued support of our investors, we are now fully resourced to transition from a discovery-stage research company to a clinical-stage organization. Our mission is to provide safe, effective, and accessible treatments for patients suffering from a range of neurological conditions, and this capital ensures we remain on track for our first-in-human trials in 2027.”
Dr. Witowski continued, “We are pleased to see support by the Administration to increase access to psychedelic drugs and expedite the development of innovative treatments with the recently signed U.S. Executive Order, ‘Accelerating Medical Treatments for Serious Mental Illness.’ With the renewed focus from key regulatory agencies, we look forward to working with them to fully develop PSIL-006.”
The infusion of capital follows the achievement of several significant milestones, including:
The appointment of distinguished neuroscience industry expert Magali Haas, MD/PhD, as Chief Medical Officer;
Receipt of an NIH funding award of up to $2 million for IND-enabling studies of PSIL-006 in alcohol use disorder (AUD)
Execution of a strategic licensing agreement with atai Life Sciences (now AtaiBeckley) for its DMT patent portfolio.
About Psilera Psilera is a leading biopharmaceutical company pioneering next-generation psychedelics and neuroplastogens. Their programs span a wholly owned pipeline of novel therapeutic neuroplastogens, including the lead compound PSIL-006. With a deep commitment to scientific excellence and to improving the patient experience, Psilera pioneers and engineers novel therapies through next-generation precision neuropharmacology. Learn more by visiting www.psilera.com.
Contact Information: Investors: Monique Kosse, Gilmartin Group [email protected]
Transformation Capital leads $21M investment in Solstice, enabling pharma brands to slash medical, legal, and regulatory marketing review cycles from weeks to less than 48 hours
NEW YORK, May 28, 2026 — Solstice, the AI-native marketing agency accelerating pharma commercialization, today announced it has raised $21 million in Series A funding led by Transformation Capital with participation from Twelve Below, Virtue Ventures and others. The round brings total funding to approximately $25 million. The capital will fuel go-to-market expansion, accelerate product development and enable Solstice to grow its team across product and customer-facing functions. Few business challenges are as high-stakes and time-sensitive as commercializing a new drug or medical product.
Biopharma companies are projected to spend more than $100 billion on commercialization efforts. Yet, the process of transforming clinical evidence into compliant marketing campaigns has barely changed over the past decades. A single marketing asset, even something as routine as an email, often takes three months to move through medical, legal and regulatory (MLR) review. With shrinking patent exclusivity windows, every additional month of delay means fewer patients receiving a therapeutic.
“We built Solstice to help life sciences teams bring therapeutics to market faster by unifying content creation, medical review and performance insights in a single AI-native system that generates beautiful content, grounds every claim in clinical evidence before MLR review and measures what content will actually move the needle in driving physician and patient action,” said Aris Saxena, co-founder and CEO of Solstice. “Our customers used to run three review cycles per asset; now they run one or two at most, and content that used to take months goes out in 10 days. Most importantly, they create more personalized, higher-performing content that helps them compete in increasingly crowded biopharma markets.”
Solstice pairs AI-native technology with in-house subject-matter experts to replace traditional workflows among marketing agencies, regulatory teams and in-house marketers. The platform ingests a brand’s clinical data, FDA documents and approved literature to build a grounded understanding of the product to quickly generate digital campaigns, programmatic ads and patient and healthcare provider communications. Every asset is created and reviewed using a combination of Solstice’s proprietary pharmaceutical marketing models as well as the company’s in-house experts for both compliance and taste, and is scored on its likelihood of MLR approval for review before it reaches the regulatory team. Solstice then measures content performance to predict the highest-performing assets and produce novel content that drives physician and patient engagement. The result is a faster path to attributable, compliant content without sacrificing the expertise pharma brands require.
“Before Solstice, getting a single marketing asset through MLR could take weeks of back-and-forth that delayed launch and healthcare provider outreach,” said Kristine Saffrin, marketing director, Alexion Pharmaceuticals. “Now we move from draft to approved in days, which means our team can actually deliver on the personalization and pace a modern brand demands.”
Solstice customers launch campaigns 12 times faster than they would via traditional agencies, enabling content to move from concept to MLR submission in under 48 hours and be market-ready in roughly 10 days. As a result, teams are producing nearly three times more high-quality, tasteful and effective content per quarter and reducing the average number of MLR reviews per asset from 3.2 rounds to 1.2 rounds.
“Bringing a new drug to market is one of the most valuable and heavily regulated processes in healthcare, yet the commercialization workflow has barely changed in decades,” said Vinay Shah, Partner and Founding Team Member at Transformation Capital. “Solstice is using AI to fix that — helping pharma brands move faster without compromising compliance. Customers are already seeing real results via faster reviews and meaningful cost savings. We’re thrilled to lead this round and partner with the Solstice team.”
The Series A follows a year of rapid commercial growth for the company, which now serves over a dozen pharmaceutical companies, including several of the top 20 pharmaceutical brands across therapeutic areas, including oncology, immunology and metabolic diseases.
About Solstice: Solstice is the AI-native marketing agency for pharma brands. The company pairs AI technology with in-house experts to generate, review and activate compliant marketing content at speed, replacing the traditional handoffs between agencies, regulatory teams and in-house marketers. Headquartered in New York, Solstice is backed by leading investors including Transformation Capital, Twelve Below, Virtue Ventures, Ford Street Ventures, Go Global Ventures, Cory Capital and others. For more information, visit https://www.solsticehealth.co/.
The company is building an AI-native platform that connects every payor-provider contract to the operations that depend on it, from negotiation and modeling to payment and reconciliation.
NEW YORK, May 28, 2026 — Kubera Health today announced it has raised $6.5 million in seed funding led by Upfront Ventures, with participation from Company Ventures, Dria Ventures, and SemperVirens. The company is building the contract-to-payment system of record for American healthcare: the missing infrastructure layer between the agreements that govern payment and the systems that execute them.
Kubera Health is building the contract-to-payment system of record for American healthcare: the missing infrastructure layer between the agreements that govern payment and the systems that execute them.
Every dollar moving between a payor and a provider is governed by thousands of pages of contracts, amendments, fee schedules, and payor policies, with carveouts, modifiers, and reimbursement rules buried throughout. In nearly every healthcare organization, those documents live in shared drives, disconnected from the claims systems that process payment. Providers lose between3% and10% of net revenue annually to inaccurate payments, while payors spend billions adjudicating the resulting disputes. Patients are left paying out-of-pocket with little to no explanation.
For decades, the industry has tried to manage around this disconnection rather than fix it. Healthcare’s response to payment disputes has historically been more staff. Now we’ve added AI: payor models trained to deny and downgrade within seconds, provider models trained to appeal and recode in response. The administrative burden grows with every cycle — what the industry now calls the “Battle of the Bots.” Kubera is building the layer underneath: a preventative and auditing system that brings accountability to payment trends and enforces what every contract actually says.
Kubera turns a customer’s full set of payor-provider agreements into structured rules that run continuously against claims and payment data. Contract Intelligence and the Contract Modeler organize the document portfolio, track deadlines, benchmark rates and terms against the market, and let contracting teams model changes against historical claims before they sign. Payment Auditing and Policy Intelligence apply that logic against actual payments, surface discrepancies with the contract reasoning attached, and bring payor coverage rules into the same system to prevent disputes before they start.
Roja Garimella, MD, founded Kubera Health after concluding from inside Humana and Commonwealth Care Alliance that healthcare’s biggest barriers to better care weren’t clinical, but financial.
“I went into medicine expecting to spend my career on care delivery. The hardest problems I ran into were the ones nobody was supposed to talk about: billion-dollar payment decisions running through spreadsheets, and an industry betting its future on value-based care without the contract and payment infrastructure to support it. That’s what Kubera is building,” said Roja Garimella, founder and CEO at Kubera Health.
Kubera Health partners primarily with mid-to-large health systems with complex managed care operations. Every customer to date has expanded their engagement with Kubera, including Los Angeles-based Hollywood Presbyterian Medical Center.
“Kubera has become an extension of our managed care team,” said Deb DuRoff, FACHE, Vice President of Managed Care at Hollywood Presbyterian Medical Center. “Our contracts and reimbursement methodologies are some of the most complex in healthcare, and we needed a partner sophisticated enough to model them and validate payments against them.”
The thesis behind the round is that fixing this layer is structurally different from improving the workflows on top of it.
“Kubera is rebuilding healthcare’s broken payment foundation, turning contracts into code that runs against claims, so payors and providers finally operate from the same source of truth instead of fighting over the gaps between two different ones,” said Kevin Zhang, General Partner at Upfront Ventures. “Roja, a physician who has lived this problem from the payor, provider, and clinical sides, is exactly the founder to build it.”
The new funding will support continued investment in Kubera’s product, engineering, and go-to-market teams as the company expands its capabilities across value-based care and other novel contract structures, builds out a dedicated payment recovery layer, and grows adoption across health systems, provider organizations, and payor networks.
About Kubera Health
Kubera Health is building the contract-to-payment system of record for American healthcare. The platform translates payor-provider agreements into structured rules and applies them continuously to claims and payment data, giving payors and providers a shared source of truth about what should be paid and what actually was. Learn more atkuberahealth.com.
About Upfront Ventures
Upfront Ventures is proud to be an early investor and long-term partner to tech founders and startups. Founded in 1996 in Los Angeles with investing professionals based in LA and San Francisco, Upfront has backed teams across all technology sectors including hard tech, healthcare, gaming, fintech, SaaS, and developer tools. We invest about half of our capital in the fast-growing Southern California ecosystem, with the balance across the country as well as investments in Europe. Learn what we’re about at upfront.com.
Marking a decade of growth, Payslip delivers 60% CAGR alongside strong EBITDA positivity as it scales enterprise payroll operations
New Customer Wins Including Flix and Zalando Reflect Rising Global Demand for Payroll Control
DUBLIN, May 28, 2026 — Payslip, the Global Payroll Control Platform trusted by multinational companies to standardise, automate, and scale payroll operations, has secured new financing to support its continued international expansion and product innovation.
The financing round is from London-headquartered Salica Investments, amidst strong competition from several other providers in the market that tendered for the business, and will enable Payslip to hire more staff to increase with demand.
Payslip SLT 2026
The raise follows a sustained period of growth, with 60% CAGR in recent years alongside strong EBITDA positivity. Meanwhile, Payslip remains on its trajectory of doubling revenue every two years. This momentum was further reflected recently as Payslip marked the two-year anniversary of its strategic partnership with Deloitte, against a backdrop of growing global demand for unified, AI-led payroll infrastructure. As organisations respond to expanding pay transparency and compliance requirements – including the EU Pay Transparency Directive – multinational employers are increasingly seeking centralised, audit-ready payroll data and greater operational visibility across fragmented global systems. Today, the Payslip Control Platform automates more than 1.3 million monthly payslips across over 125 countries, powering more than €5 billion in payroll payments worldwide.
This positions the company to scale further, expanding internationally while continuing to invest in its enterprise grade automation platform and AI technology. As enterprise scale, payroll is no longer just operational, it is a control layer across finance, compliance, and workforce data.
“This year marks our 10th year in business,” said Fidelma McGuirk, Founder and CEO of Payslip. “Over the past decade, we’ve built a platform trusted by the world’s leading multinational organisations to bring control and consistency to one of the most mission critical business areas. As the Fourth Industrial Revolution reshapes global business operations, automation and operational efficiency across core enterprise functions have become essential for competitiveness. Organisations are under growing pressure to gain greater visibility, standardisation and control across increasingly complex international payroll environments, particularly as AI accelerates the pace of operational change.”
“Payslip’s automation and AI capabilities are already delivering up to 55% efficiency gains for multinational organisations, helping enterprise teams simplify complexity, strengthen compliance and operate with greater agility at global scale. This investment enables us to further accelerate innovation in AI and continue expanding our international presence as demand for intelligent payroll infrastructure continues to grow,” McGuirk added.
Building on Payslip Alpha, AI is now embedded directly into payroll workflows, identifying anomalies, standardising inputs, and adapting in real time across jurisdictions. As usage scales, the platform develops a deeper understanding of country rules, exceptions, and integrations, strengthening accuracy, resilience, and control over time.
This momentum is reflected in a growing roster of global brands, including Cloudera, Just Eat Takeaway and EQT, alongside new customers Flix and Zalando, supported by strong retention and continued expansion across the existing customer base.
The raise marks a defining moment in Payslip’s ten-year journey, reflecting confidence in the company’s continued growth, accelerating enterprise adoption, and expanding role at the centre of global payroll operations.
About Payslip
Payslip is a global payroll technology company that gives multinational enterprises greater control, automation and visibility across complex payroll operations.
Founded in 2016 by Fidelma McGuirk and headquartered in County Mayo, Ireland, Payslip helps global organisations standardise and automate global payroll, unify multi-country payroll data, and streamline reporting at scale. Its Global Payroll Control Platform integrates with HCM, accounting and ERP systems to ensure seamless enterprise-wide data flows across the enterprise, supporting centralised control, real-time visibility and enterprise-grade compliance.
Payslip Alpha, the company’s AI suite, is transforming payroll operations through advanced AI, automation and integration capabilities.
Payslip is backed by $21 million in funding from investors including Salica Investments, Tribal VC, Frontline Ventures, MiddleGame Ventures and Mouro Capital.
Investment values Blulabs at $160 million pre-money and supports continued growth across manufacturing, logistics, technology, and customer service infrastructure
MIAMI, May 27, 2026 — Lodestone Capital today announced that it has led a $7 million investment in Blulabs, a global supply chain and manufacturing partner serving leading airlines, distributors, hospitality groups, retailers, and Fortune 500 customers. The investment values Blulabs at $160 million pre-money and will support the company’s continued expansion of its global supply chain platform, technology infrastructure, and customer service capabilities.
Remy Garson (left), Marc Garson (center), and Cole Garson (right)
Blulabs has grown at approximately 40% CAGR since 2020 and is projected to reach $250 million in revenue through a capex-light global manufacturing and logistics model. The company operates across 10 countries and 4 continents, providing customers with reliable sourcing, manufacturing, freight coordination, inventory planning, and supply chain execution in categories where consistency, speed, and cost control are critical.
Built by the Garson family over multiple decades, Blulabs has developed a differentiated operating model designed for a world where supply chain volatility has become the norm, mastering the art of turning chaos into certainty. Through a diversified supplier base, flexible manufacturing footprint, and deeply embedded customer relationships, the company helps large enterprises maintain continuity, protect pricing, and reduce disruption across complex global supply chains.
“We have spent years building a supply chain platform for customers who cannot afford disruption,” said Remy Garson, Co-CEO of Blulabs. “Our role is to be the partner behind the scenes making sure products arrive, costs are managed, and customers can continue operating without interruption. The world is becoming more complex, not less, and we believe companies need partners who can combine global reach, execution discipline, and constant adaptability.”
Blulabs operates largely as an invisible partner to its customers, supporting the brand equity and operational needs of major commercial airlines, hospitality groups, janitorial and sanitation distributors, and retailers. The company has secured multi-year, high-share customer relationships by focusing on reliability, responsiveness, and supply chain problem-solving rather than building a consumer-facing brand of its own.
The partnership with Lodestone Capital marks an important step in the institutionalization of Blulabs’ family-led platform. Lodestone will support Blulabs as it continues to scale its governance, strategic planning, technology capabilities, and capital infrastructure while preserving the entrepreneurial culture that has driven the company’s growth.
A portion of the capital will be used to accelerate the development of Blulabs’ proprietary AI-enabled supply chain intelligence platform. The system is designed to improve visibility across purchase orders, production schedules, freight routing, inventory planning, and customer commitments. By tracking key variables across the supply chain, the platform is expected to help Blulabs anticipate potential disruptions, optimize decisions in real time, and provide customers with greater reliability in volatile markets.
“Blulabs is exactly the type of business Lodestone Capital was built to support,” said Will Tenenbaum, Founder and CEO of Lodestone Capital. “It is a founder- and family-led company with exceptional customer relationships, a highly practical operating model, and a large opportunity to scale. The last several years have shown that supply chain resilience is no longer a nice-to-have. For many large enterprises, it is mission-critical. Blulabs has built the trust, infrastructure, and execution capability to become an indispensable partner to those customers.”
Cole Garson, Co-CEO of Blulabs, said the financing represents both a growth milestone and a continuation of the company’s founding principles.
“Our father, Marc Garson, built this company on relationships, execution, and the belief that the best supply chain partners create peace of mind for their customers,” said Cole Garson, Co-CEO of Blulabs. “This investment allows us to build on that foundation with more technology, more data, and more institutional capability. We are not changing who we are. We are strengthening the platform so we can serve our customers at an even higher level.”
Marc Garson, Founder and Chairman of Blulabs, added: “The business has always been about trust. Customers trust us because we solve problems, keep our commitments, and stand behind them when markets are difficult. This partnership gives the next generation the resources and support to continue building Blulabs to the next level.”
About Blulabs
Blulabs LLC is a global supply chain, sourcing, manufacturing, and logistics partner serving leading airlines, hospitality companies, distributors, retailers, and Fortune 500 customers. The company supports customers through a diversified global manufacturing network, flexible logistics infrastructure, and customer-focused execution model designed to deliver reliability, cost control, and continuity across complex supply chains. Blulabs operates across 10 countries and 4 continents and is headquartered in Miami, Florida.
About Lodestone Capital
Lodestone Capital partners with founder-led and family-owned businesses to support growth, governance, capital strategy, and long-term value creation. Lodestone Capital is part of the broader Lodestone platform, which includes Lodestone Global, Lodestone Family Advisors, and E3 focused on governance-driven value creation.
TORONTO, May 27, 2026 — MaxWave Capital Inc. (“MaxWave”) today announced a strategic investment in Arken Innovations Inc. (“ARKEN”), a Canadian deep-tech company building industrial decision intelligence through its proprietary Knowledge Fusion Engine™.
The investment extends beyond a portfolio position. For MaxWave, ARKEN becomes part of the firm’s operating infrastructure, embedded across diligence, portfolio operations, and value creation, so that the analytical capability developed through one transaction compounds intelligently across the broader platform.
ARKEN LOGO
The Discipline Private Markets Now Require
Private markets are expanding rapidly. New vehicles, new investor types, and broader distribution have extended access significantly. But scale changes the economics of decision-making, and access without discipline produces a different category of risk. The industry’s most durable competitive advantage has never been leverage or deal flow — it has been the quality, rigor, and consistency of decisions made under uncertainty.
In the industrial sectors MaxWave targets — defence, energy, healthcare, and advanced manufacturing — the cost of fragmented knowledge and poor decisions is not measured in basis points. Gartner estimates poor data quality alone costs organizations an average of $12.9 million annually — before accounting for the decisions made on information that was incomplete, fragmented, or simply wrong. In high-stakes operational environments, those are not productivity losses. They are safety incidents, compliance failures, and mission breakdowns.
ARKEN’s Knowledge Fusion Engine™ addresses this directly by transforming fragmented data, documentation, and institutional expertise into structured, auditable, and goal-aligned operational intelligence. Built on Goal-Oriented Knowledge Management (GOKM) — a methodology refined over two decades — ARKEN makes decisions traceable, explainable, and measurable in environments where that rigor is non-negotiable.
A Differentiated Operating Thesis
For MaxWave, this investment reflects a foundational conviction: that markets systematically misprice complexity, compliance, and knowledge fragmentation — and that unlocking value in modern industrial businesses requires not only capital and operational expertise, but a new decision infrastructure.
“Private equity has traditionally relied on experience, pattern recognition, and operational playbooks. What ARKEN enables is the institutionalization of decision-making itself — not as a concept, but as deployable infrastructure. When knowledge, human expertise, and outcomes are fully traceable and compounding across a portfolio, the gap between what passive capital can observe and what an embedded operating model can execute against becomes structural. That is our operating model.” — Dr. Peter J. Balafas, Managing Partner, MaxWave Capital
Built for Environments Where Being Wrong Is Not an Option
Most AI platforms are built to generate answers. ARKEN is built differently. Its architecture separates probabilistic perception — where the intelligence lives — from a deterministic decision layer where governance is enforced. The system surfaces its own uncertainty at every point of user interaction, because hiding that uncertainty does not eliminate the liability. It transfers it invisibly to the operator.
This is not a design philosophy. It is an architectural constraint. ARKEN treats the underlying intelligence as a probabilistic component and wraps deterministic governance around it — so that in regulated industries, users always know what the system knows, what it does not know, and what it is not permitted to decide on their behalf.
“In the industries we serve — maritime, defence, healthcare, legal — a wrong answer isn’t a bad user experience. It’s a grounded vessel, a missed compliance window, a patient harmed. Most AI platforms will give you an answer. ARKEN is built to know when not to. Refusal, traceability, and governance are the foundation, not features. That’s why MaxWave’s partnership matters — we’re setting the standard for decisions where being wrong is not an option.” — Sam Sanandaji, Founder and CEO, Arken Innovations
Together, MaxWave and ARKEN will embed decision infrastructure across investments, operations, and portfolio companies — advancing a model for private market value creation built on operational co-ownership, engineering-grade diligence, and institutional-grade accountability.
Arken Innovations is a Canadian deep-tech company building governed decision intelligence for regulated industries where operational failures carry irreversible consequences. Its Knowledge Fusion Engine™ — ARKEN’s probabilistic retrieval and synthesis layer — operates within a deterministic governance envelope that enforces authorization, source-traceability, audit, and governed refusal. Hiding model uncertainty does not reduce liability; it transfers it invisibly to the operator. ARKEN’s governance layer cannot be overridden by probabilistic outputs. Engineered for aerospace & defence, healthcare, maritime, energy, advanced manufacturing, and legal environments. Learn more at www.thearken.com
About MaxWave Capital Inc.
MaxWave Capital is an operator-led Independent Sponsor focused on control-oriented investments and special situations across North America and selectively across the UK and broader EMEA. Built by founders with backgrounds in deep technology, capital markets, and complex cross-border transactions — with collective experience spanning over nine completed transactions across 15+ countries and more than $5 billion in aggregate transaction value — MaxWave targets businesses that are structurally mispriced, operationally challenged, or undergoing transition: situations where engineering-grade diligence and operational co-ownership unlock value beyond the reach of passive capital. Current portfolio positions span high-stakes AI, market-integrity intelligence and regtech, and technology-enabled industrial platforms. Learn more at www.maxwavecapital.com
Strategic Partnership Will Fuel Growth While Maintaining Focus on Quality
NORTH CANTON, Ohio, May 27, 2026 — Captive Radiology, a leading provider of turnkey diagnostic imaging solutions, today announced a strategic growth investment from RC Capital, a healthcare-focused growth investment firm. This partnership enables Captive Radiology to accelerate its expansion, enhance service capabilities, and continue delivering high-quality imaging solutions that improve patient access to critical diagnostic imaging and theranostic services.
The partnership comes at a time of increasing demand for advanced diagnostic imaging services, particularly in specialized areas such as the emerging theranostic space. Captive Radiology has been at the forefront of this trend, recently expanding into PET-CT imaging for prostate cancer detection and monitoring, as well as other critical applications across additional specialties.
Founded in 2003, Captive Radiology has built a reputation for excellence in providing comprehensive imaging solutions, including project management, operations management, staffing, quality assurance, and state-of-the-art imaging equipment. The company currently operates more than 30 imaging partnerships across nearly 20 states, serving hospitals, physician groups, and specialized healthcare facilities. Dave Kelly will continue as an owner and leader of the business, ensuring continuity of the company’s mission and values.
“We’ve experienced tremendous growth over the past several years, and this partnership with RC positions us to meet the demand from even more healthcare partners and their patients,” says Dave Kelly, CEO of Captive Radiology. “RC Capital shares our commitment to improving patient outcomes through better access to diagnostic imaging. Their deep healthcare expertise and growth-focused approach make them the ideal partner as we enter this exciting next chapter. I’m energized to continue leading this business alongside our talented team.”
RC Capital’s investment reflects the firm’s focus on building high-potential healthcare companies that improve delivery of care and patient outcomes. With over 30 years of experience in healthcare investing, RC Capital brings extensive domain expertise in healthcare services and medical devices, a unique combination that aligns perfectly with Captive Radiology’s integrated approach to diagnostic imaging.
“Captive Radiology represents exactly the type of company we seek to partner with. It is a business with a proven track record, strong growth momentum, and an unwavering commitment to quality patient care,” says Carter McNabb, Managing Partner at RC Capital. “Dave and his team have built an exceptional business that addresses a critical need in the healthcare system. We’re excited to support their vision for expansion while preserving the customer-first culture and operational excellence that have made Captive so successful to date.”
Vitaly Goldfeder, Principal at RC Capital, added, “Healthcare providers increasingly need long-term partners who can deliver these solutions quickly and efficiently. Captive Radiology’s full-service model is accelerating access to innovative theranostic modalities that are becoming the standard of care across more areas of the healthcare ecosystem. We look forward to working with Dave and the entire Captive Radiology team to accelerate growth across the country.”
About Captive Radiology
Captive Radiology specializes in providing high-quality, turnkey imaging solutions to improve access to and enhance the timeliness of best-in-class patient care. The company handles every aspect of radiology integration, ensuring seamless execution from planning to implementation. With a comprehensive service approach that includes project management, operations management, radiology staffing, quality assurance, and state-of-the-art equipment, Captive Radiology has served hospitals and physician groups since 2003. The company currently operates over 30 imaging partnerships across nearly 20 states, providing PET-CT, MRI, and other advanced diagnostic imaging and theranostic services. Captive Radiology’s mission is to improve partners’ ability to diagnose and treat patients in a more timely, cost-effective manner while always placing partners’ needs first. For more information, visit www.captiveradiology.com.
About RC Capital
RCC is focused on building high-growth businesses that empower sustainable change in healthcare. We seek to be a business partner first and a capital provider second, investing significant human capital to leverage our domain expertise, our network of healthcare thought leaders and deep relationships with health systems assembled over our 30+ year history. For more information, visit www.rccf.com.
Contact: Captive Radiology Dave Kelly, CEO (330) 966-0500 [email protected]
TL’s nonprofit venture model transforms philanthropic capital into local investment and a permanent funding engine for San Diego
SAN DIEGO, May 27, 2026 — TL Foundation, San Diego’s philanthropic venture fund, named Kris Lichter as chief executive officer to lead the next phase of the region’s economic and innovation funding engine. TL Foundation is bringing together San Diego leaders across all sectors to establish an evergreen source of capital that will grow over time, enabling local innovative companies to start, scale and transform San Diego’s future. (https://SanDiegoTLF.org)
Kris Lichter has been named CEO of TL Foundation, San Diego’s philanthropic innovation fund.
TL Foundation’s funding engine accelerates San Diego innovation growth and strengthens economy.
San Diego is one of the nation’s leading innovation hubs, with world-class companies, talent and research. TL Foundation was created to accelerate and expand that capability by putting philanthropic funding to work into San Diego’s most promising startups. As these companies grow, they and their employees contribute to the broader community.
When a TL portfolio company reaches a successful outcome or exit, all proceeds return to the fund for reinvestment for further deployment across the San Diego innovation ecosystem. This investment flywheel expands the evergreen capital base and creates a more self-reliant regional economy. Over time, a $15 million fund can become $100 million, then $300 million. Every success helps fund the next one with a positive impact throughout the community.
“San Diego has extraordinary people and companies that care deeply about this city. They have chosen to build their businesses and raise their families here. They’re committed to this town and we’re committed to them,” Lichter said. “Our opportunity is to put capital to work that empowers our local entrepreneurs to accelerate their value creation and success, which enables San Diego to grow stronger and more capable far into the future. This is built by San Diegans for San Diegans.”
A San Diego native, Lichter said the work is deeply personal and rooted in socioeconomic best practices from his global experience. Families seek to build their lives in places with strong job opportunities, quality education, vibrant communities and a stable foundation. When those elements are in place, the region becomes more self reliant, sustainable and future proof.
Lichter brings more than two decades of experience leading and investing in emerging technology initiatives and scaling innovation worldwide. He previously served as chief executive officer of Ardica Technologies and held senior global roles at IBM. He is also an operating partner at Victory Six Advisors and co-founder of DuMonde Ventures.
“Kris brings the rare combination of local commitment, operating experience and global perspective that this moment requires,” said Andy Ballester, chairman of TL Foundation. “San Diego has strong innovation activity right now. Kris understands how to scale it and continue advancing a system that supports company growth and long-term regional success.”
TL Foundation’s initial funding has been led by San Diego philanthropists Buzz Woolley and Malin Burnham, with support from many of the city’s leaders in startups, technology and life sciences. In just over a year, TL has invested in six high-potential companies: Condor Software, Looq, Papillon Therapeutics, Resolute Science, Proper Voltage and Welby Health. These early efforts show how local capital drives company growth, job creation and broader economic strength.
Under Lichter’s leadership, TL Foundation will focus on expanding its capital base, increasing the pace of investment and broadening participation across the community.
“TL started as a unique idea that had never been done before. Kris is the right person to help grow this into something much bigger for San Diego,” said Mike Krenn, managing director of Prebys Ventures and founder of TL Foundation. “We’re asking people building across San Diego to step in and help. This is a rare opportunity where a donation can grow over time and keep giving back. The more we invest now, the faster we can grow something truly significant. If you share TL’s vision and are committed to San Diego’s future, we want to hear from you.”
LOS ANGELES, May 27, 2026 — Ember LifeSciences, Inc., (“Ember”) a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors.
The Ember Cube 2 was recently named ‘Best of the Best’ by the Red Dot Award for product design
The investments follow Ember LifeSciences’ previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Ember Cube 2, an award-winning, reusable, modular solution designed to bring greater control and visibility to cold chain logistics through real-time monitoring and cloud-based tracking.
“Investments from Amgen and TDF Ventures provide us with the deep industry insights needed to scale our logistics platform rapidly,” said Clay Alexander, founder and CEO of Ember LifeSciences. “Their investments mark a turning point as we expand our global footprint and bring a new level of precision to healthcare delivery.”
The pharmaceutical cold chain faces billions of dollars in annual losses due to temperature excursions, a problem that the industry is under more pressure to solve as more medicines and vaccines require temperature-controlled distribution. Ember aims to address these challenges through its reusable shipping platform. Its latest Ember Cube 2 was recently named “Best of the Best” by the Red Dot Award for product design.
Ember’s existing customers and investors include leading pharmaceutical distributors and pharmacies including CVS Health, Cardinal Health, Chartwell and USADA. In addition to the Ember Cube 2, its product suite includes the flagship Ember Cube, which was named a 2024 TIME Magazine Invention of the Year and a 2024 Fast Company World Changing Idea.
Financial terms of the new investments were not disclosed. The company’s total Series A funding to date now stands at $27 million.
About Ember LifeSciences Ember LifeSciences initially launched as an offshoot of Ember Technologies’ “Ember,” the design-led temperature control brand and maker of the award-winning temperature control mug, which has surpassed half a billion dollars in total sales to date. Ember LifeSciences seeks to redefine global medicine distribution through leveraging Ember’s proprietary temperature control technology to improve the way we transport life-saving medicines and vaccines around the world. To learn more about Ember LifeSciences, visit emberlifesciences.com.
